Aurinia Pharmaceuticals Inc.

AUPH

NASDAQ

Healthcare

Biotechnology

Edmonton, BC, CA130 employeesauriniapharma.com

$15.64

+0.17(1.13%)

Mkt Cap $2.1B

$7.20

$16.37

52-Week Range

At a Glance

AI-generated

Revenue breakdown: Product (89.7%), License Collaboration And Royalty Revenue (6.6%), Service (3.7%).

8-K

Aurinia Pharmaceuticals entered into a merger agreement to acquire Kezar Life Sciences for $6.955 cash per share plus one CVR, with tender offer commencing by April 13, 2026, and closing expected in Q2 2026.

$2.1B

Market Cap

$280M

Revenue

$284M

Net Income

Employees130

Fundamentals

How The Business Makes Money

Revenue by Segment

Product89.7%($646M)

License Collaboration And Royalty Revenue6.6%($48M)

Service3.7%($27M)

Revenue by Geography

US91.1%($632M)

JP8.9%($62M)

Activity

What Changed Recently

Management Change

Mar 22, 2026

Departures of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment

Material Agreement

Apr 2, 2026

| Entry into a Material Definitive Agreement. Agreement and Plan of Merger On March 30, 2026, Aurinia Pharma U.S., Inc., a Delaware corporation (“Parent”), ente

Financial Results

Feb 25, 2026

shall not be incorporated by reference in any of Aurinia's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or aft

Company Profile

CIK0001600620

ISINCA05156V1022

CUSIP05156V102

Phone12507084272

Address4464 Markham Street, Edmonton, BC, V8Z 7X8, CA

SEC EDGAR